Market accessOfficial

AIFA: Italian public pharmaceutical spending hits €13.42bn in first half of 2026

🇮🇹 AIFA · Thu 19 Nov 2026

AIFA's definitive monitoring report puts January–June public drug spending at 19.07% of the provisional national health fund, with retail spending above its ceiling in several regions.

Italy's public pharmaceutical expenditure (retail dispensing through the convenzionata channel, direct purchases and oxygen) totalled €13,417.6 million in the first six months of 2026, according to AIFA's definitive monitoring report. That equals 19.07% of the provisional 2026 national health fund (FSN) figure, which the Ministry of Health communicated by note no. 12829 of 27 July 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.